Mainz Biomed N.V. announced a partnership with Trusted Health Advisors (THA). Mainz Biomed is in late-stage clinical development of a highly accurate and easy-to-use nucleic acid-based detection test for colorectal cancer (CRC) screening diagnostics that it intends to distribute, if approved, via the Company's unique business model of marketing products via partnerships with third-party laboratories. In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.

The Company currently commercializes its first-generation test in Europe and in select international territories through its product ColoAlert via partnerships with third-party laboratory laboratories. The partnership with THA will be led by Drs. Jay Wohlgemuth and Ray Tabibiazar, Managing Partners of the firm.